Advertisement
PMN vs SYRE
Which Stock Would AI Choose? ProMIS Neurosciences (PMN) vs. Spyre Therapeutics (SYRE) Stock Comparison
Key Takeaways
- Both PMN and SYRE are clinical-stage biotechnology companies with no product revenue, yet their market positioning, cash resources, and recent momentum differ sharply.
- SYRE has delivered multiple positive Phase 2 readouts in 2026 and holds a roughly $1.15 billion cash position, while PMN is a much smaller, earlier-stage micro-cap developer.
- Tickeron AI Verdict: SYRE — its stronger trend consistency, deeper cash runway, and dense catalyst schedule currently outweigh PMN's profile.
- SYRE shares have appreciated sharply over the past year, while PMN has shown greater volatility against a modest float and heavy share-count expansion.
- Get more context on PMN Major News and PMN Today's Price Move, as well as SYRE Major News and SYRE Today's Price Move, to track these tickers in real time.
- For an algorithmic perspective on market opportunities, explore Trending AI Robots.
Introduction
Investors scanning the biotechnology landscape often encounter two very different profiles wearing the same "clinical-stage" label. PMN (ProMIS Neurosciences) is a micro-cap focused on antibody and vaccine therapies for neurodegenerative diseases such as Alzheimer's. SYRE (Spyre Therapeutics) is a well-capitalized developer of antibody therapies for inflammatory bowel disease (IBD) and rheumatic conditions. This stock comparison is relevant for traders seeking relative performance signals and for long-term investors weighing pipeline depth, capital runway, and catalyst density. Although both remain pre-revenue, their risk-reward profiles and recent momentum differ enough to make a side-by-side evaluation meaningful.
PMN Overview and Recent Performance
ProMIS Neurosciences develops precision antibody and therapeutic vaccine candidates for misfolded protein diseases. Its lead asset, PMN310, is a monoclonal antibody (mAb) — a laboratory-made immune protein — targeting toxic amyloid-beta oligomers in Alzheimer's disease, alongside earlier programs for amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). The company is headquartered in Toronto and maintains a relatively small team.
In recent market activity, PMN has traded within a notably wide 52-week range, reflecting the high sensitivity of micro-cap biotechs to financing events and clinical news. The company has reported no product revenue, and its outstanding share count has expanded substantially over the past year as it raised capital to fund research. Institutional ownership has grown, and sell-side analysts at firms including Guggenheim and HC Wainwright have maintained Buy ratings. However, the stock's negative beta and thin float can amplify both upswings and drawdowns, making it a higher-volatility positioning relative to better-funded peers.
SYRE Overview and Recent Performance
Spyre Therapeutics is a Waltham, Massachusetts-based biotech advancing a portfolio of engineered antibody candidates targeting validated pathways in IBD and rheumatic diseases. Its lead programs — SPY001 (anti-α4β7), SPY002 (anti-TL1A), and SPY003 (anti-IL-23) — are being tested as monotherapies and combinations in the Phase 2 SKYLINE study in ulcerative colitis (UC), while SPY072 targets inflammatory rheumatic conditions.
Over recent weeks, SYRE has benefited from a string of positive data. SPY001 and SPY002 each met their primary endpoints with statistically significant histopathology improvements and clinically meaningful remission rates. The company ended its latest quarter with approximately $1.15 billion in cash and marketable securities, supported by an April public offering, and management has guided that runway into the second half of 2029. This combination of clinical momentum and balance-sheet strength has driven substantial share appreciation, though it has also pushed valuation to a premium relative to book value.
Trending AI Robots
For traders who prefer a systematic approach, Tickeron's Trending AI Robots page curates a selection of AI trading bots from a library of hundreds. These bots trade thousands of different tickers across varied strategies, timeframes, and risk profiles, each with its own performance statistics and asset focus. Rather than surfacing every available bot, the page highlights only those deemed most suitable for current market conditions, helping users filter signal from noise. Whether you are evaluating individual names like PMN and SYRE or scanning the broader market, exploring Trending AI Robots can offer an additional, data-driven lens on opportunity.
Head-to-Head Comparison
The two companies occupy opposite corners of the biotech spectrum. PMN is a micro-cap with a narrower, earlier pipeline concentrated in neurodegenerative disease, an area characterized by high clinical failure risk but substantial unmet need. Its cash position is adequate for near-term development but modest compared with larger rivals, and its frequent equity raises have diluted existing shareholders. In contrast, SYRE operates a broader, mid-stage pipeline across multiple validated immunology targets, backed by a cash balance that extends its runway for years and enables multiple concurrent readouts.
On momentum, SYRE has delivered concrete, market-moving catalysts, while PMN remains more dependent on early-stage data and financing cycles. The trade-off is valuation: SYRE trades at a rich premium after its rally, whereas PMN's lower market capitalization may offer a different risk-return asymmetry. Sector exposure also differs, with neurodegeneration and immunology carrying distinct regulatory and competitive dynamics.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor SYRE in the current environment. Its trend consistency, robust cash runway, and a dense schedule of near-term clinical catalysts provide a more stable foundation than PMN's earlier-stage, capital-constrained profile. While PMN retains meaningful upside if its neurodegenerative programs advance, the AI's probabilistic weighting of momentum, stability, and catalysts tilts toward SYRE at this time.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PMN is a Hold and SYRE is a Hold.
PMN's RSI Oscillator sits in oversold zone for 1 day
It is expected that a price bounce should occur soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator is in the oversold zone. Keep an eye out for a move up in the foreseeable future.
Following a +14.46% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 154 of 186 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PMN as a result. In 101 of 106 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for PMN turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 48 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 30, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.545) is normal, around the industry mean (3.104). P/E Ratio (-0.238) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
SYRE's Stochastic Oscillator stays in overbought zone for 8 days
The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for SYRE moved out of overbought territory on October 29, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 23 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYRE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for SYRE entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on SYRE as a result. In 67 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 86%.
The Moving Average Convergence Divergence (MACD) for SYRE just turned positive on October 20, 2026. Looking at past instances where SYRE's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
SYRE moved above its 50-day moving average on October 26, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for SYRE crossed bullishly above the 50-day moving average on October 29, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 79%.
Following a +7.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where SYRE advanced for three days, in 259 of 298 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
SYRE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (8.821) is normal, around the industry mean (3.104). P/E Ratio (-49.761) is within average values for comparable stocks, (-0.958). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (129.907) among similar stocks. P/S Ratio (526.316) is also within normal values, averaging (439.647).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. SYRE’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 43 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SYRE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PMN | SYRE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 1 | 81 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 92 Overvalued | 5 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 99 | 96 | |
PRICE GROWTH RATING 1..100 | 97 | 35 | |
P/E GROWTH RATING 1..100 | 6 | 43 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
SYRE's Valuation (5) in the Pharmaceuticals Major industry is significantly better than the same rating for PMN (92) in the null industry. This means that SYRE’s stock grew significantly faster than PMN’s over the last 12 months.
SYRE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as PMN (100) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.
SYRE's SMR Rating (96) in the Pharmaceuticals Major industry is in the same range as PMN (99) in the null industry. This means that SYRE’s stock grew similarly to PMN’s over the last 12 months.
SYRE's Price Growth Rating (35) in the Pharmaceuticals Major industry is somewhat better than the same rating for PMN (97) in the null industry. This means that SYRE’s stock grew somewhat faster than PMN’s over the last 12 months.
PMN's P/E Growth Rating (6) in the null industry is somewhat better than the same rating for SYRE (43) in the Pharmaceuticals Major industry. This means that PMN’s stock grew somewhat faster than SYRE’s over the last 12 months.
| PMN | SYRE | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | 2 days ago 85% |
| Stochastic ODDS (%) | 2 days ago 86% | 2 days ago 90% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 86% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 90% | 2 days ago 88% |
| Advances ODDS (%) | 6 days ago 83% | 7 days ago 87% |
| Declines ODDS (%) | 2 days ago 90% | 2 days ago 87% |
| BollingerBands ODDS (%) | 2 days ago 85% | 2 days ago 81% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
PMN’s FA Score shows that 1 FA rating(s) are green while SYRE’s FA Score has 1 green FA rating(s).
- PMN’s FA Score: 1 green, 4 red.
- SYRE’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
PMN’s TA Score shows that 4 TA indicator(s) are bullish while SYRE’s TA Score has 6 bullish TA indicator(s).
- PMN’s TA Score: 4 bullish, 5 bearish.
- SYRE’s TA Score: 6 bullish, 4 bearish.
Price Growth
PMN (@Biotechnology) experienced а -62.73% price change this week, while SYRE (@Biotechnology) price change was +2.80% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -2.06%. For the same industry, the average monthly price growth was -12.02%, and the average quarterly price growth was -17.00%.
Reported Earning Dates
PMN is expected to report earnings on Nov 11, 2026.
SYRE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Biotechnology (-2.06% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
PMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, PMN has been closely correlated with ABOS. These tickers have moved in lockstep 76% of the time. This A.I.-generated data suggests there is a high statistical probability that if PMN jumps, then ABOS could also see price increases.
| Ticker / NAME | Correlation To PMN | 1D Price Change % | ||
|---|---|---|---|---|
| PMN | 100% | -9.37% | ||
| ABOS - PMN | 76% Closely correlated | +14.09% | ||
| CNSP - PMN | 51% Loosely correlated | -9.80% | ||
| GYRE - PMN | 46% Loosely correlated | +3.84% | ||
| SYRE - PMN | 44% Loosely correlated | -1.09% | ||
| BBIO - PMN | 42% Loosely correlated | +0.06% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MCHS | 33.69 | 0.31 | +0.92% |
| Matthews China Innovators Active ETF (MCHS) | |||
| IFV | 23.91 | 0.16 | +0.69% |
| First Trust Dorsey Wright International Focus 5 ETF (IFV) | |||
| KOKU | 133.25 | N/A | N/A |
| Xtrackers MSCI Kokusai Equity ETF (KOKU) | |||
| DDFN | 20.72 | -0.01 | -0.04% |
| Innovator Equity Dual Directional 15 Buffer ETF - November (DDFN) | |||
| CIBR | 96.75 | -4.28 | -4.24% |
| First Trust NASDAQ Cybersecurity ETF (CIBR) | |||